Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) — Najib Ben Khaled (2025) | RDL Network
Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Lorenza Rimassa, Stephen L. Chan, Bruno Sangro, George Lau, Masatoshi Kudo, В. В. Бредер, Marı́a Varela, Oxana Crysler, Mohamed Bouattour, Tu Van Dao, Adilson Faccio, Junji Furuse, Long-Bin Jeng, Yoon‐Koo Kang, R. Kate Kelley, Michael J. Paskow, Mallory Makowsky, Di Ran, Alejandra Negro, Ghassan K. Abou‐Alfa
Masatoshi Kudo, Lorenza Rimassa, Stephen L. Chan, Bruno Sangro, George Lau, В. В. Бредер, Marı́a Varela, Oxana Crysler, Mohamed Bouattour, Tu Van Dao, Adilson Faccio, Junji Furuse, Long-Bin Jeng, Yoon‐Koo Kang, R. Kate Kelley, Michael J. Paskow, Mallory Makowsky, Di Ran, Alejandra Negro, Ghassan K. Abou‐Alfa
S.L. Chan, Bruno Sangro, R.K. Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, Enrico N. De Toni, J. Furuse, Y-K. Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Tu Van Dao, S. Chiradoni Thungappa, В. В. Бредер, Y.V. Ostapenko, María Reig, Charu Gupta, Ghassan K. Abou‐Alfa
B. Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, M. Yarchoan, Enrico N. De Toni, J. Furuse, Yoon‐Koo Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Tu Van Dao, S.C. Thungappa, В. В. Бредер, Y. Ostapenko, María Reig, M. Makowsky, Michael J. Paskow, Charu Gupta, ,
Bruno Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, Enrico de Toni, Junji Furuse, Yoon‐Koo Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Thông Dao, Satheesh Chiradoni Thungappa, В. В. Бредер, Y. Ostapenko, María Reig, M. Makowsky, Charu Gupta, Alejandra Negro, Ghassan K. Abou‐Alfa
Discussion(0)
No comments yet. Be the first to comment.